{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Engel AR"],"funding":["Intramural NIH HHS"],"pagination":["243-52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2914112"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["405(1)"],"pubmed_abstract":["Tick-borne encephalitis (TBE) is a severe disease affecting thousands of people throughout Eurasia. Despite the use of formalin-inactivated vaccines in endemic areas, an increasing incidence of TBE emphasizes the need for an alternative vaccine that will induce a more durable immunity against TBE virus (TBEV). The chimeric attenuated virus vaccine candidate containing the structural protein genes of TBEV on a dengue virus genetic background (TBEV/DEN4) retains a high level of neurovirulence in both mice and monkeys. Therefore, attenuating mutations were introduced into the envelope (E(315)) and NS5 (NS5(654,655)) proteins, and into the 3' non-coding region (Delta30) of TBEV/DEN4. The variant that contained all three mutations (vDelta30/E(315)/NS5(654,655)) was significantly attenuated for "],"journal":["Virology"],"pubmed_title":["The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome."],"pmcid":["PMC2914112"],"funding_grant_id":["ZIA AI000637-18"],"pubmed_authors":["Rumyantsev AA","Pletnev AG","Speicher JM","Maximova OA","Heiss B","Murphy BR","Engel AR"],"additional_accession":[]},"is_claimable":false,"name":"The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome.","description":"Tick-borne encephalitis (TBE) is a severe disease affecting thousands of people throughout Eurasia. Despite the use of formalin-inactivated vaccines in endemic areas, an increasing incidence of TBE emphasizes the need for an alternative vaccine that will induce a more durable immunity against TBE virus (TBEV). The chimeric attenuated virus vaccine candidate containing the structural protein genes of TBEV on a dengue virus genetic background (TBEV/DEN4) retains a high level of neurovirulence in both mice and monkeys. Therefore, attenuating mutations were introduced into the envelope (E(315)) and NS5 (NS5(654,655)) proteins, and into the 3' non-coding region (Delta30) of TBEV/DEN4. The variant that contained all three mutations (vDelta30/E(315)/NS5(654,655)) was significantly attenuated for ","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Sep","modification":"2025-04-21T14:43:39.919Z","creation":"2019-03-27T00:32:54Z"},"accession":"S-EPMC2914112","cross_references":{"pubmed":["20594569"],"doi":["10.1016/j.virol.2010.06.014"]}}